UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2023

Larimar Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-36510 (Commission File Number) 20-3857670 (IRS Employer Identification No.)

Three Bala Plaza East Bala Cynwyd, Pennsylvania (Address of Principal Executive Offices)

19004 (Zip Code)

Registrant's Telephone Number, Including Area Code: (844) 511-9056

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	
Title of each class	Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	lrmr	Nasdag Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On May 15, 2023, Larimar Therapeutics, Inc. (the "*Company*") announced its financial results and operational highlights for the first quarter ended March 31, 2023. A copy of the Press Release (as defined in Item 8.01 below) is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 8.01 Other Events.

Press Release

On May 15, 2023, the Company issued a press release announcing preliminary top-line data from its phase 2 trial's 25 mg cohort showing increases in frataxin levels in patients with Friedreich's ataxia and first quarter 2023 financial results (the "*Press Release*"), which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Investor Presentation

On May 15, 2023, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Below is a list of exhibits included with this Current Report on Form 8-K.

Exhibit N	o. Document
99.1	Press Release issued by Larimar Therapeutics, Inc. on May 15, 2023*
99.2	Larimar Therapeutics, Inc. Corporate Presentation, dated May 15, 2023*
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)
*	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Larimar Therapeutics, Inc.

Date: May 15, 2023

By: /s/ Carole S. Ben-Maimon, M.D.

Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer



Exhibit 99.1

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results

- Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated when administered daily for 14 days and then every-other-day thereafter until day 28
- Daily subcutaneous injections of 25 mg CTI-1601 for 14 days led to increases in frataxin levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells)
- Median placebo-adjusted increases from baseline of 3.5 pg/µg and 0.9 pg/µg in frataxin levels observed in skin and buccal cells, respectively, with 14 days of daily dosing of CTI-1601
- Larimar has submitted data to FDA and will meet with the Agency to discuss next steps; update expected in Q3 2023
- Company management to host webcast and conference call today at 8:00 a.m. ET

Bala Cynwyd, PA, May 15, 2023 – Larimar Therapeutics, Inc. ("Larimar") (Nasdag: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced preliminary top-line data from the 25 mg cohort of its Phase 2, four-week, placebo-controlled, dose exploration trial of CTI-1601 in participants with Friedreich's ataxia (FA). Participants in the trial's 25 mg cohort (n=13) were randomized to receive subcutaneous injections of 25 mg CTI-1601 (n=9) or placebo (n=4) daily for 14 days and then every-other-day thereafter until day 28. Data from the cohort indicate CTI-1601 was generally well tolerated and showed increases in frataxin (FXN) levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14.

In skin, a median placebo-adjusted increase from baseline of 3.5 pg/µg in frataxin levels was observed on day 14 (frataxin concentration normalized to total protein). Of the seven CTI-1601-treated participants with quantifiable levels of frataxin in skin at both baseline and day 14, all seven had increases in skin frataxin concentrations, compared to none of the four placebo participants with quantifiable levels of frataxin in skin at both baseline and day 14. In buccal cells, a median placebo-adjusted increase from baseline of 0.9 pg/µg in frataxin levels was observed on day 14 (frataxin concentration normalized to total protein). Of the seven CTI-1601-treated participants with quantifiable levels at both baseline and day 14, five had increases in buccal cell frataxin in buccal cells at both baseline and day 14, five had increases in buccal cell frataxin concentrations, compared to neither of the two placebo participants with quantifiable levels of frataxin in buccal cells at both baseline and day 14.

In a non-interventional study that used the same sampling technique and assay as Larimar's Phase 2 trial to measure frataxin levels in 60 homozygous healthy volunteers, median frataxin concentrations observed in skin and buccal cells were 16 pg/µg and 8 pg/µg, respectively (frataxin concentration normalized to total protein). Larimar therefore estimates phenotypically healthy heterozygous carriers of the FA-causing gene to have median frataxin concentrations of approximately 8 pg/µg and 4 pg/µg in skin and buccal cells, respectively, based on published literature indicating heterozygous carriers have frataxin levels that are approximately 50% of those of homozygous healthy people.

Larimar's Phase 2 data and non-interventional study results follow Phase 1 data that showed dose-dependent increases in frataxin levels in peripheral tissue with daily dosing of 50 and 100 mg of CTI-1601 for at least 7 days, and no detectable increase in FXN levels with daily dosing of 25 mg of CTI-1601 for only 4 days.

Larimar has submitted the data from the trial's 25 mg cohort to FDA and has a meeting scheduled with the Agency for later this quarter to discuss the information needed to gain clearance to initiate a 50 mg cohort in the Phase 2 trial.

"Our preliminary Phase 2 data provide the first clinical indication that a 25 mg dose of CTI-1601 can increase frataxin levels in peripheral tissues, building upon our proof-of-concept Phase 1 results," said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar. "Importantly, the frataxin increases achieved with a relatively low 25 mg dose in our Phase 2 trial suggest a continuous daily dosing regimen is preferred for maintaining increases achieved with 25 mg CTI-1601. I would like to thank all those who participated in our trials and look forward to our upcoming meeting with the FDA later this quarter."

The median change from baseline in FXN levels at day 14 (last day of daily dosing) and day 28 (end of treatment and after switching to every other day dosing) in the Phase 2 trial are shown in the table below.

	TABLE 1: FXN	I Change from Baseline	e in Skin Biopsi	ies [#]		
		Units: pg FXN / µg total pi	otein			
	Data presente	d as: median (25 th percentil	e, 75 ^m percentile)	(n)		
Dose Group		Day 14			Day 28	
Placebo	-0.66	(-1.08, -0.37)	(n=4)	-0.30	(-0.90, 0.77)	(n=4)
25 mg CTI-1601	2.81	(2.16, 3.32)	(n=7)	2.28	(-0.03, 2.71)	(n=7)

[#]Day 14 and 28 skin biopsies were not collected from one CTI-1601 treated participant who discontinued treatment and one CTI-1601 treated participant had FXN levels below quantifiable levels at day 14 and day 28

		ν Change from Baseline Units: pg FXN / μg total pro d as: median (25 th percentile	otein			
Dose Group		Day 14			Day 28	
Placebo	-0.35	(-0.58, -0.13)	(n=2)	0.01	(-0.52, 0.53)	(n=2)
25 mg CTI-1601	0.56	(-0.28, 0.64)	(n=7)	0.03	(-0.66, 0.86)	(n=6)

[#] For the placebo group, one participant had buccal cell FXN levels below quantifiable levels at baseline and one participant had buccal cell FXN levels below quantifiable levels at day 14 and day 28

[#]For 25 mg group, day 28 buccal FXN were not collected from one participant who discontinued treatment and two participants had buccal FXN levels below quantifiable levels at baseline

Pharmacokinetic data suggest that steady state was achieved by day 14 in the Phase 2 trial's 25 mg cohort, which was the last day of daily dosing. Safety data indicate that CTI-1601 was generally well tolerated in the Phase 2 trial's 25 mg cohort. A summary of safety data from the cohort is shown below:

- No serious adverse events were reported
- No important medical events were reported
- · One severe adverse event was reported, which was an allergic reaction to study drug that resolved with standard treatment
- Of the nine participants dosed with CTI-1601, eight completed the trial, with one participant withdrawing due to the aforementioned allergic reaction that
 resolved with standard treatment
- The most common adverse events were mild and moderate injection site reactions. At least one injection site reaction was seen in two of four placebo treated participants and in all CTI-1601 treated participants.

Dr. Ben-Maimon added, "Our Phase 2 results add to our safety database indicating that CTI-1601 is generally well tolerated. Thirty-seven adults with FA have been dosed with CTI-1601 across our Phase 1 and 2 trials, with 35 completing treatment, one withdrawing due to an allergic reaction, and another withdrawing after a single 50 mg dose in the multiple ascending dose trial due to mild to moderate nausea and vomiting. We believe the safety, pharmacokinetic, and pharmacodynamic data generated to date support evaluation of a 50 mg dose of CTI-1601 in our Phase 2 trial and look forward to discussing our findings with the U.S. Food and Drug Administration (FDA) at our meeting later this quarter."

The initiation of additional cohorts in the Phase 2 trial and/or the initiation of other clinical trials of CTI-1601 are contingent on a review of data and analyses from the Phase 2 trial's 25 mg cohort by the FDA, in

accordance with a partial clinical hold on the CTI-1601 program first put into place after a full clinical hold was lifted in September 2022. Larimar has submitted the data from the trial's 25 mg cohort to FDA and has a meeting scheduled with the Agency for later this quarter to discuss the information needed to gain clearance to initiate a 50 mg cohort in the Phase 2 trial. Larimar expects to provide an update on the next steps for the CTI-1601 program in the third quarter of 2023, after it has received feedback from the upcoming FDA meeting.

First Quarter 2023 Financial Results

In addition to preliminary top-line data from its Phase 2 trial's 25 mg cohort, Larimar today announced financial results for the first quarter of 2023.

As of March 31, 2023, the Company had cash and cash equivalents totaling \$111.5 million.

The Company reported a net loss for the first quarter of 2023 of \$6.5 million, or \$0.15 per share, compared to a net loss of \$8.9 million, or \$0.49 per share, for the first quarter of 2022.

Research and development expenses for the first quarter of 2023 were \$4.6 million compared to \$5.8 million for the first quarter of 2022. The decrease in research and development expenses compared to the prior year period was primarily driven by a decrease of \$0.7 million in nonclinical development costs a decrease of \$0.4 million in drug manufacturing costs, and a decrease of \$0.1 million in clinical trial expense.

General and administrative expenses were \$3.1 million in both the first quarter of 2023 and the first quarter of 2022. Decreases in recruiting and professional service fees were offset by increases in stock-based compensation expense and other personnel-related expenses.

Conference Call and Webcast

Larimar will host a conference call and webcast today, May 15, 2023 at 8:00 a.m. ET. To access the webcast, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13738708, or click on this link and request a return call. Following the live event, an archived webcast will be available on the "Events & Presentations" page of the Larimar website.

About CTI-1601

CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich's ataxia who are unable to produce enough of this essential protein. CTI-1601 has been granted Rare Pediatric Disease designation, Fast Track designation and Orphan Drug designation by the U.S. Food and Drug Administration (FDA), Orphan Drug Designation by the European Commission, and a PRIME designation by the European Medicines Agency.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to Larimar's expectations regarding its ability to resolve the partial clinical hold imposed by the FDA related to CTI-1601, Larimar's ability to develop and commercialize CTI-1601 and other planned product candidates, Larimar's planned research and development efforts, including the timing of its CTI-1601 clinical development plan and other matters regarding Larimar's business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, Larimar's ability to successfully engage with the FDA and satisfactorily respond to requests from the FDA for further information and data regarding the CTI-1601 clinical trial including the FDA review of data from cohort one from the Phase 2 dose exploration trial and FDA's agreement to escalate the dosing in cohort two, the timing and outcomes of Larimar's interactions with the FDA concerning the partial clinical hold, the success, cost and timing of Larimar's product development activities, nonclinical studies and clinical trials, including CTI-1601 clinical milestones; that preliminary and top-line clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of CTI-1601 may not be predictive of the results or success of later clinical trials, and assessments; manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar's ability and the ability of thirdparty manufacturers Larimar engages, to optimize and scale CTI-1601's manufacturing process; Larimar's ability to obtain regulatory approvals for CTI-1601 and future product candidates; Larimar's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar's ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar's management's views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.

Investor Contact:

Joyce Allaire LifeSci Advisors jallaire@lifesciadvisors.com (212) 915-2569

Company Contact:

Michael Celano Chief Financial Officer mcelano@larimartx.com (484) 414-2715

Larimar Therapeutics, Inc.

Consolidated Balance Sheet (unaudited)

(unautied)				
	March	31,	Deceml	ber 31,
	2023		202	22
Assets				
Current assets:				
Cash and cash equivalents	\$	111,524	\$	26,825
Marketable securities				91,603
Prepaid expenses and other current assets		1,940		2,311
Total current assets		113,464		120,739
Property and equipment, net		753		831
Operating lease right-of-use assets		2,719		2,858
Restricted cash		1,339		1,339
Other assets		632		638
Total assets	\$	118,907	\$	126,405
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable	\$	695	\$	1,686
Accrued expenses		6,726		8,408
Operating lease liabilities, current		589		611
Total current liabilities		8,010		10,705
Operating lease liabilities		4,656		4,797
Total liabilities		12,666		15,502
Commitments and contingencies (See Note 8)				
Stockholders' equity:				
Preferred stock; \$0.001 par value per share; 5,000,000 shares authorized				
as of March 31, 2023 and December 31, 2022; no shares issued and				
outstanding as of March 31, 2023 and December 31, 2022		—		—
Common stock, \$0.001 par value per share; 115,000,000 shares				
authorized as of March 31, 2023 and December 31, 2022; 43,269,200 shares issued and outstanding as of				
March 31, 2023 and December 31, 2022		43		43
Additional paid-in capital		264,329		262,496
Accumulated deficit		(158,131)		(151,605)
Accumulated dench Accumulated other comprehensive loss		(130,131)		(151,003)
				(51)

Total stockholders' equity	106,241		110,903
Total liabilities and stockholders' equity	\$ 118,907	\$	126,405


Larimar Therapeutics, Inc.

Consolidated Statements of Operations

(In thousands, except share and per share data)

(unaudited)

	Three Month	s Ended March 31,	
	2023	2	022
Operating expenses:			
Research and development	\$ 4,562	\$	5,806
General and administrative	3,075		3,081
Total operating expenses	7,637		8,887
Loss from operations	 (7,637)		(8,887)
Other income (expense), net	1,111		(56)
Net loss	\$ (6,526)	\$	(8,943)
Net loss per share, basic and diluted	\$ (0.15)	\$	(0.49)
Weighted average common shares outstanding, basic and diluted	43,897,603		18,338,853
Comprehensive loss:			
Net loss	\$ (6,526)	\$	(8,943)
Other comprehensive gain:			
Unrealized gain on marketable securities	31		_
Total other comprehensive gain	31		_
Total comprehensive loss	\$ (6,495)	\$	(8,943)



Forward-Looking Statements

This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. ("Company") and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited to Larimar's expectations regarding its ability to resolve the partial clinical hold imposed by the FDA related to CTI-1601, Larimar's ability to develop and commercialize CTI-1601, Larimar's planned research and development efforts, including the timing of its CTI-1601 clinical development plan and other matters regarding Larimar's business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the Company's ability to successfully engage with the FDA and satisfactorily respond to requests from the FDA for further information and data regarding the CTI-1601 clinical trial including the FDA review of data from cohort one from the Phase 2 dose exploration trial and FDA's agreement to escalate the dosing in cohort two, the timing and outcomes of Larimar's interactions with the FDA concerning the partial clinical hold, the success, cost and timing of Larimar's product development activities, nonclinical studies and clinical trials, including CTI-1601 clinical milestones; that preliminary and top-line clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of CTI-1601 may not be predictive of the results or success of later clinical trials, and assessments; Larimar's ability and the ability of third-party manufacturers Larimar engages, to optimize and scale CTI-1601's manufacturing process; Larimar's ability to obtain regulatory approvals for CTI-1601 and future product candidates; Larimar's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar's ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent Larimar's management's views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.



Preliminary Top-line Data from 25 mg cohort of Ph 2 Trial

Participants dosed daily for 14 days and then every-other-day until end of treatment (day 28)

Safety and PK	Safety data indicate CTI-1601 was generally well tolerated in the cohort PK data suggest steady state was achieved by day 14
Frataxin (FXN) Levels	Median placebo-adjusted increase from baseline of 3.5 pg/µg in FXN levels in skin with 14 days daily dosing Median placebo-adjusted increase from baseline of 0.9 pg/µg in FXN levels in buccal cells with 14 days daily dosing Data build on proof-of-concept Phase 1 results
Next Steps	A meeting between Larimar and FDA is scheduled to discuss the information needed to gain clearance to initiate a 50 mg cohort in the Phase 2 trial Update on CTI-1601 program expected in Q3 2023
Larimar	3

Investment Highlights



Clinical-stage biotechnology company with a novel protein replacement therapy platform Focused on addressing unmet needs in Friedreich's ataxia (FA) and potentially other complex rare diseases based on a platform technology backed by a strong intellectual property portfolio



Lead candidate: CTI-1601, a recombinant fusion protein designed to deliver frataxin to mitochondria Orphan Drug (US & EU), Rare Pediatric Disease (US), Fast Track (US), & PRIME (EU) designations for FA



Double-blind, placebo-controlled Phase 1 proof-of-concept trials in individuals with FA complete Data show that CTI-1601 was generally well tolerated when dosed daily for up to 13 days & dose dependent increases in frataxin (FXN) levels from baseline compared to placebo in all evaluated tissues with daily dosing



Placebo-controlled, Phase 2, 4-week dose exploration study in individuals with FA 25 mg cohort data show that CTI-1601 was generally well tolerated & increases in FXN from baseline compared to placebo in skin & buccal cells. Per partial clinical hold, further clinical studies contingent on FDA review of data



Strong financial foundation with projected cash runway into 2H 2024 March 31, 2023 cash - \$111.5M High-quality institutional investor base includes founding investor Deerfield Management



Friedreich's Ataxia (FA)

Rare and Progressive Disease

Caused by genetic defect resulting in low levels of frataxin

- Patients with FA only produce ~20-40% of normal frataxin levels depending on the tissue, sampling technique, and assay considered¹
- Affects ~20,000 patients globally, with ~5,000 patients in the U.S. and majority of the remaining patients in the EU

Approximately 70% of patients present before age 14

Initial symptoms may include unsteady posture, frequent falling and progressive difficulty in walking. By the time symptoms occur, heart damage may have already occurred. Progressive disease: symptoms worsen and patients are eventually confined to a wheelchair with speech becoming hesitant and jerky (often referred to as "scanning of speech")

Life expectancy of 30-50 years

Early death usually caused by heart disease

No available therapies increase frataxin levels

· Only treatment approved for FA does not address frataxin deficiency


LRMR continues to have a strong relationship with Friedreich's Ataxia Research Alliance
Dedicated FA patient advocacy group focused on treatments for FA



•

1. E.C. Deutsch et al. Molecular Genetics and Metabolism 101 (2010) 238-245

Dose Dependent Increases in FXN Levels Observed in Skin and Buccal Cells in Phase 1






*FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations are normalized to total cellular protein content in each sample; Data represent median and 25th and 75th percentiles; FXN levels from baseline, Day 4, & Day 13 measurements are shown for data derived from the 25 mg cohort; FXN levels from baseline, Day 7 & Day 13 measurements are shown for data derived from the 50 & 100 mg cohorts; Sample collection days varied in each cohort per the trial protocol

6

Increases in FXN Correlated with Increasing CTI-1601 Dose in Phase 1 Trial



Larimar Therapeutics

*FXN levels measured via detection of peptide derived from mature FXN. FXN concentrations are normalized to total cellular protein content in each sample; #For 100 mg group, two participants did not have sample at Day 13. °For 25 mg group, one participant did not have sample at Day 4. °For 50 mg group, day 7 buccal cells were not collected from one participant who discontinued treatment and one participant did not have sample.

Ongoing Phase 2, Four-week Dose Exploration Study

Goal: Further characterize PK/PD and assess safety to inform long-term dose and dose regimen

	Treatment Schedule						
	28-day Treatment Period						
1 2 3	4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	27 28					
= Administration of CTI-1601 or placebo							
= No Adn	ninistration						
	Study Details						
Population	Ambulatory and non-ambulatory Friedreich's ataxia patients ≥18 years of age. CTI-1601 treatment naïve or participated (if eligible) in a previous Larimar study.						
Dose	Cohort 1: 25 mg (dosing complete) Cohort 2: Dose escalation contingent on a review of Cohort 1 data by FDA and IDMC.						
Key Endpoints	Frataxin levels in peripheral tissue, PK, PD, safety and tolerability. PD endpoints include lipid profiles and gene expression data.						
Number of Patients	Cohort 1: Enrolled 13 participants randomized 2:1 to receive CTI-1601 (n=9) or placebo (n=4). Planned Cohort 2: Designed to enroll ~12-15 participants randomized 2:1 to receive CTI-1601 or placebo						
Timing	Expect to provide update on next steps in Q3 2023.						
	IDMC: Independent data monitoring committee	8					

Demographics

Demographics similar between Phase 1 and Phase 2 trials of CTI-1601

Parameter, n (%)	Placebo (N=4)	CTI-1601 25 mg (N=9)	Overall (N=13)
Mean Age (SD) (Years)	34.0 (9.20)	37.8 (14.93)	36.6 (13.16)
Male	2 (50.0%)	5 (55.6%)	7 (53.8%)
White	4 (100.0%)	8 (88.9%)	12 (92.3%)
Other	0	1 (11.1%)	1 (7.7%)
Not Hispanic or Latino	3 (75.0%)	8 (88.9%)	11 (84.6%)
Hispanic or Latino	1 (25.0%)	1 (11.1%)	2 (15.4%)
Mean BMI (SD) (kg/m²)	23.66 (3.235)	25.26 (6.262)	24.77 (5.417%)
Previously participated in a CTI-1601 trial	1 (25.0%)	4 (44.4%)	5 (38.5%)

Disease Characteristics

Parameter	Statistic	Placebo (N=4)	CTI-1601 (n=9)	Overall (n=13)
Age at Symptom Onset (year	rs)			
	n	4	8	12
	Mean (SD)	14.5 (4.93)	13.0 (10.47)	13.5 (8.77)
	Median	14.5	10.0	11.0
	Q1, Q3	11, 19	8, 13	9, 15
	Min, Max	9, 20	5, 38	5, 38
Age at Diagnosis (years)				
	n	4	9	13
	Mean (SD)	17.5 (5.57)	18.6 (11.20)	18.2 (9.58)
	Median	16.5	16.0	16.0
	Q1, Q3	14, 22	14, 20	14, 20
	Min, Max	12, 25	5, 42	5, 42
Time Since Diagnosis (years)			
	n	4	9	13
	Mean (SD)	16.08 (5.965)	18.49 (11.523)	17.75 (9.938)
	Median	13.42	14.32	13.50
	Q1, Q3	12.9, 19.3	12.8, 21.6	12.8, 21.6
	Min, Max	12.5, 25.0	5.4, 45.0	5.4, 45.0



10

CTI-1601 appeared to be generally well tolerated in Phase 2 trial's 25 mg cohort

Summary of Phase 2 trial safety data (25 mg cohort):

25 mg CTI-1601 or placebo were administered subcutaneously daily for 14 days and then every other day until day 28. 13 participants were dosed in the trial (9 active, 4 placebo). Of the 9 CTI-1601-treated participants, 8 completed the trial with 1 withdrawing due to an allergic reaction to study drug, which resolved with standard treatment


- Phase 2 and Phase 1 data consistent. 37 different adults with FA have been dosed with CTI-1601; data indicate CTI-1601 is generally well tolerated
- No serious adverse events. No important medical events. 1 severe adverse event (allergic reaction that resolved with standard treatment as referenced above).
- The most common adverse events were mild and moderate injection site reactions (at least one injection site reaction was seen in 50% of placebo participants and in 100% of CTI-1601 participants)

Pharmacokinetic Data

Suggest steady state achieved by day 14

Increases in FXN Levels Observed in Skin Biopsies

Median placebo-adjusted increase from baseline of 3.5 pg/µg in FXN levels in skin with 14 days daily dosing






*FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations are normalized to total cellular protein content in each sample; Data for left graph represent median and 25th and 75th percentiles. #: Subject 0006 (treated with CTI-1601) discontinued from study at Day 14 (Skin was not collected since post dose); Subject 0002 (treated with CTI-1601) had a FXN concentration value <lower limit of quantitation (LLOQ) at Day 14

Increases in FXN Levels Observed in Buccal Cells

Median placebo-adjusted increase from baseline of 0.9 pg/µg in FXN levels in buccal cells with 14 days daily dosing





*FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations are normalized to total cellular protein content in each sample; Data for left graph represent median and 25th and 75th percentiles. Subject 0006 (treated with CTI-1601) discontinued from study at Day 14 (Skin was not collected since post dose); Subject 0002 (treated with CTI-1601) had a baseline and day 14 value < lower limit of quantitation (LLOQ); Subject 0007 (treated with placebo) had a FXN concentration value <LLOQ at baseline; Subject 0015 (treated with placebo) had a FXN concentration value <LLOQ at Day 14.

13

CTI-1601 Clinical Development Plan

Update on next steps expected in Q3 2023

Planned Trials Include:



Phase 2 four-week dose exploration study. Dosing in Cohort 1 is complete. Meeting with FDA scheduled for Q2 2023.





Jive open-label extension trial for eligible patients who participated in SAD, MAD, and/or four-week dose exploration studies.



MAD trial in patients 2 to 17 years of age. Participants eligible to screen for Jive open-label extension trial.



Global double-blind placebo-controlled pivotal trial.

CTI-1601: In Development as the First Therapeutic Intended to Increase FXN

Phase 1

Generally well tolerated; Dose-dependent increases in FXN levels observed in all evaluated tissues with 7 days of daily dosing at 50 mg and 100 mg

Phase 2

Generally well tolerated

Median placebo-adjusted increase from baseline of 3.5 pg/µg in FXN levels in skin with 14 days daily dosing Median placebo-adjusted increase from baseline of 0.9 pg/µg in FXN levels in buccal cells with 14 days daily dosing



Meeting with FDA scheduled to discuss the information needed to gain clearance to initiate a 50 mg cohort in Phase 2 trial; Expect to provide an update in Q3 2023

15